Small molecule inhibitors of hematopoietic prostaglandin D2 synthase (HPGD2S) for inflammatory disease including DMD and asthma.

Key Features

  • Potent, selective and orally administrable small molecule compounds
  • Down-regulates multiple clinically validated targets
  • Selective expression resulting in improved safety – HPGD2S is primarily expressed peripheral tissues (mast and Th2 cells)
  • First in class opportunity for the treatment of asthma and allergic rhinitis

Back to available technologies

Contact us

To enquire about this Available Technology, please contact us.